Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
activated charcoal + simethicone (Amdis Healthsciences)
- Development stage
- Unknown
- Lead developer
- Amdis Healthsciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Deburp is a fixed-dose combination capsule containing activated charcoal (250 mg) and simethicone (80 mg), developed by Amdis Healthsciences. It is indicated for the treatment of symptoms associated with excess intestinal gas, including flatulence, bloating, abdominal discomfort, belching, hiccups, and post-operative gaseous distention. Simethicone acts as an antiflatulent by reducing the surface tension of gas bubbles, facilitating their coalescence and expulsion. Activated charcoal acts as an adsorbent, binding gas molecules and reducing the overall volume of intestinal gas.
- Brand names
- DeburpDepurb
Beyond the preview
Go deeper on activated charcoal + simethicone (Amdis Healthsciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on activated charcoal + simethicone (Amdis Healthsciences).